Financing advances development of Prota’s peanut allergy remission therapy in preparation for a Phase 3 clinical trial MELBOURNE, Jan 16, 2024 – (ACN Newswire) – Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, today announced financing of US$21 million in […]
Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up to half of the projected ColiFin® Phase 3 development costs, including those involving both COPILOT and COPA SGI has invested in Spexis as part of the ColiFin® P3 clinical trial partnership financing; additional investments from other investors expected in the […]
AUM Biosciences (AUM) today announced the successful completion of $27 million series A funding round. This will fuel AUM’s vision of developing a world class biotech pipeline focused on drugging what many consider as the undruggable targets, as well as addressing the need to delay and overcome resistance to targeted drugs in oncology.
Travecta Therapeutics, announces today it has raised an additional $12 million in financing, closing its Series A round at a total of $27 million.